Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.51
-0.1500-9.04%
Post-market: 1.540.0255+1.69%19:50 EDT
Volume:91.95K
Turnover:143.71K
Market Cap:6.35M
PE:-0.32
High:1.64
Open:1.63
Low:1.51
Close:1.66
52wk High:8.19
52wk Low:1.51
Shares:4.20M
Float Shares:3.61M
Volume Ratio:0.12
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7923
EPS(LYR):-6.8265
ROE:-768.25%
ROA:-124.42%
PB:1.89
PE(LYR):-0.22

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Imunon, Inc.
Exchange:
NASDAQ
Establishment Date:
1982
Employees:
20
Office Location:
997 Lenox Drive,Suite 100,Lawrenceville,New Jersey,United States
Website:
http://www.imunon.com
Zip Code:
08648
Phone:
609 896 9100
Fax:
- -
Introduction:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Directors

Name
Position
Michael H. Tardugno
Director and Executive Chairman
Stacy R. Lindborg
Chief Executive Officer, President and Director
Christine Pellizzari
Independent Director
Donald P. Braun
Independent Director
Frederick J. Fritz
Independent Director
James E. Dentzer
Independent Director

Shareholders

Name
Position
Stacy R. Lindborg
Chief Executive Officer, President and Director
Jeffrey W. Church
Interim Chief Financial Officer
Douglas Faller
Chief Medical Officer
Michael H. Tardugno
Director and Executive Chairman
Susan Eylward
General Counsel and Corporate Secretary